Nuvectis receives orphan drug designation for

cholangiocarcinoma

therapy

Preview

来源: Pharmaceutical Technology

Cholangiocarcinoma

accounts for approximately 3% of all

gastrointestinal malignancies

. Credit: Explode / Shutterstock.com.

Nuvectis Pharma has received orphan drug designation from the US Food and Drug Administration (FDA) for NXP800 to treat

cholangiocarcinoma

.

NXP800, a small molecule taken orally, is currently being assessed in a Phase Ib clinical trial.

Recommended Reports

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - Camrelizumab in

Malignant Pleural Mesothelioma

GlobalData

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - Anetumab Corixetan in

Malignant Mesothelioma

GlobalData

View allCompanies IntelligenceNuvectis Pharma IncSRC IncView all

The study is designed to explore the drug candidate’s clinical activity as a potential treatment for platinum-resistant,

ARID1a

-mutated ovarian carcinoma.

NuvectisNuvectis has already received fast track designation for the NXP800 development programme.

It is also developing another drug candidate, NXP900, a new small molecule inhibitor targeting the SRC/YES1 kinases.

The FDA has cleared the IND for NXP900 and a Phase Ia dose escalation trial is yet to commence.

Nuvectis chairman and CEO Ron Bentsur stated: “NXP800 is an oral small molecule with a novel mechanism of action that has demonstrated robust activity in several preclinical

cancer

models, including

ARID1a-mutated ovarian, endometrial and gastric carcinomas

ARID1a

-mutated ovarian, endometrial and gastric carcinomas, as well as

cholangiocarcinoma

.

“This orphan drug designation is an important milestone in our journey toward our mission of developing NXP800 for the treatment of serious conditions of unmet medical need in

oncology

.”

Cholangiocarcinoma

is a

biliary tract cancer

, which emerges in the biliary tree epithelium.

With an annual incidence of nearly 8,000 to 10,000 in the US, it accounts for around 3% of all

gastrointestinal malignancies

.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。